Skip to main content
SpringerLink
Log in

Management of Patients Co-Infected with Chronic Hepatitis B (CHB) and the Human Immunodeficiency Virus (HIV)

  • Chapter
  • First Online:
Chronic Viral Hepatitis

Part of the book series: Clinical Gastroenterology ((CG))

  • 891 Accesses

Abstract

Key Principles

Certain populations with CHB present additional clinical complexities. These include populations co-infected with the human immunodeficiency virus (HIV) chronic hepatiti B (CHB).

CHB does not appear to affect the progression of HIV infection; conversely, HIV infection does adversely influence several aspects of the natural history of CHB.

Current guidelines recommend that all HIV positive patients should be tested for the hepatitis B surface antigen (HBsAg), and that all HIV positive individuals who are seronegative for markers of HBV infection undergo vaccination.

The decision to treat CHB infection in HIV-infected individuals must be based on careful consideration of the need for antiretroviral therapy, the severity of liver disease, and potential adverse effects.

Liver transplantation is a feasible option for those with co-infection and advanced liver disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44(1 Suppl):S6–9.

    Article  PubMed  Google Scholar 

  2. http://www.unaids.org/wad2004/report_pdf.html Accessed March 2008.

  3. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007;22(9):1510–8.

    Article  PubMed  Google Scholar 

  4. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. Aids 2005;19(6):593–601.

    Article  PubMed  Google Scholar 

  5. Norder H, Courouce AM, Coursaget P, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47(6):289–309.

    Article  PubMed  Google Scholar 

  6. Jain MK, Comanor L, White C, et al. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. J Viral Hepat 2007;14(3):176–82.

    Article  CAS  PubMed  Google Scholar 

  7. Ramos B, Nunez M, Martin-Carbonero L, et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 2007;44(5):557–61.

    Article  PubMed  Google Scholar 

  8. Quarleri J, Moretti F, Bouzas MB, et al. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses 2007;23(4):525–31.

    Article  CAS  PubMed  Google Scholar 

  9. Westland C, Delaney Wt, Yang H, et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroentero-logy 2003;125(1):107–16.

    Article  CAS  PubMed  Google Scholar 

  10. Lo Re V, 3rd, Frank I, Gross R, et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007;44(3):315–20.

    Article  PubMed  Google Scholar 

  11. Hadler SC, Judson FN, O’Malley PM, et al. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection. J Infect Dis 1991;163(3):454–9.

    CAS  PubMed  Google Scholar 

  12. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999;29(4):1306–10.

    Article  CAS  PubMed  Google Scholar 

  13. Gilson RJ, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. Aids 1997;11(5):597–606.

    Article  CAS  PubMed  Google Scholar 

  14. Thio CL, Seaberg EC, Skolasky R, Jr., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360(9349):1921–6.

    Article  PubMed  Google Scholar 

  15. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166(15):1632–41.

    Article  PubMed  Google Scholar 

  16. Krogsgaard K, Lindhardt BO, Nielson JO, et al. The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers. Hepatology 1987;7(1):37–41.

    Article  CAS  PubMed  Google Scholar 

  17. Bodsworth N, Donovan B, Nightingale BN. The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160(4):577–82.

    CAS  PubMed  Google Scholar 

  18. Di Martino V, Thevenot T, Colin JF, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123(6):1812–22.

    Article  PubMed  Google Scholar 

  19. Sheng WH, Chen MY, Hsieh SM, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004;38(10):1471–7.

    Article  PubMed  Google Scholar 

  20. Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of chronic hepatitis B in co-infected patients. J Hepatol 2006;44(1 Suppl):S65–70.

    Article  PubMed  Google Scholar 

  21. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008;9(2):82–8.

    Article  CAS  PubMed  Google Scholar 

  22. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16):1–33; quiz CE1-4.

    PubMed  Google Scholar 

  23. Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992;14(1):27–30.

    Article  CAS  PubMed  Google Scholar 

  24. Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000;18(13):1161–5.

    Article  CAS  PubMed  Google Scholar 

  25. de Vries-Sluijs TE, Hansen BE, van Doornum GJ, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008;197(2):292–4.

    Article  PubMed  Google Scholar 

  26. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45(2):507–39.

    Article  CAS  PubMed  Google Scholar 

  27. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

  28. Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999;180(3):607–13.

    Article  CAS  PubMed  Google Scholar 

  29. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341(17):1256–63.

    Article  CAS  PubMed  Google Scholar 

  30. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339(2):61–8.

    Article  CAS  PubMed  Google Scholar 

  31. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19(11):1276–82.

    Article  CAS  PubMed  Google Scholar 

  32. Thio CL, Locarnini S. Treatment of HIV/HBV coinfection: clinical and virologic issues. AIDS Rev 2007;9(1):40–53.

    PubMed  Google Scholar 

  33. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348(9):800–7.

    Article  CAS  PubMed  Google Scholar 

  34. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348(9): 808–16.

    Article  CAS  PubMed  Google Scholar 

  35. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006;44(2):283–90.

    Article  CAS  PubMed  Google Scholar 

  36. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131(6):1743–51.

    Article  CAS  PubMed  Google Scholar 

  37. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet 2001;358(9283):718–23.

    Article  CAS  PubMed  Google Scholar 

  38. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43(6):1385–91.

    Article  CAS  PubMed  Google Scholar 

  39. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133(5):1445–51.

    Article  CAS  PubMed  Google Scholar 

  40. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45(2):307–13.

    Article  CAS  PubMed  Google Scholar 

  41. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354(10):1011–20.

    Article  CAS  PubMed  Google Scholar 

  42. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354(10):1001–10.

    Article  CAS  PubMed  Google Scholar 

  43. Tenney DJ. PKA, Rose, RE, Baldick CJ, Eggers BJ, et al. Entecavir at Five Years Shows Long-Term Maintenance of High Genetic Barrier to Hepatitis B Virus Resistance. Hepatology International 2008.

    Google Scholar 

  44. Pessoa M, Gazzard B, Huang A, et al. Entecavir in HIV/HBV co-infected patients: safety and efficacy in a phase II study (ETV-0389). Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections 2005:109.

    Google Scholar 

  45. McMahon MA, Jilek BL, Brennan TP, et al. The HBV drug entecavir – effects on HIV-1 replication and resistance. N Engl J Med 2007;356(25):2614–21.

    Article  CAS  PubMed  Google Scholar 

  46. van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;44(2):318–25.

    Article  PubMed  Google Scholar 

  47. Heathcote EJ, Gane E, DeMan R, Lee S, Flisiak R, et al. A Randomized Double-blind, Comparison of Tenofovir (TDF) versus Adefovir (ADV) for the Treatment of HBeAg positive chronic Hepatitis B (CHB): Study GS-US-174-0103. Hepatology 2007;46(4):861A.

    Google Scholar 

  48. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006;44(5):1110–6.

    Article  CAS  PubMed  Google Scholar 

  49. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006;43(3): 548–55.

    Article  CAS  PubMed  Google Scholar 

  50. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.

  51. Bonacini M. Diagnosis and management of cirrhosis in coinfected patients. J Acquir Immune Defic Syndr 2007;45 Suppl 2:S38–46; discussion S66–7.

    PubMed  Google Scholar 

  52. Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation 2008;85(3):359–68.

    Article  PubMed  Google Scholar 

  53. Norris S, Taylor C, Muiesan P, et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004;10(10):1271–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. National Institutes of Health, Bethesda, MD, USA

    Edward Doo MD & Marc Ghany MD

Authors
  1. Edward Doo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Ghany MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Hepatology, Georgetown University Hospital, Reservoir Road GUH 3800, Washington, 20007, U.S.A.

    Kirti Shetty

  2. University of Connecticut Health Center, Farmington Ave. 236, Farmington, 06030-1845, U.S.A.

    George Y. Wu

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Doo, E., Ghany, M. (2009). Management of Patients Co-Infected with Chronic Hepatitis B (CHB) and the Human Immunodeficiency Virus (HIV). In: Shetty, K., Wu, G. (eds) Chronic Viral Hepatitis. Clinical Gastroenterology. Humana Press. https://doi.org/10.1007/978-1-59745-565-7_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-565-7_9

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-934115-81-7

  • Online ISBN: 978-1-59745-565-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation